A randomized, split lesion controlled clinical study to evaluate the efficacy and safety of 308 nm laser combined with compound clobetasol propionate ointment in the treatment of stable vitiligo

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046707

Enrollment

Unknown

Registered

2021-05-27

Start date

2021-06-01

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vitiligo

Interventions

experimental group:Compound Clobetasol Propionate Ointment

control group:0.02% Clobetasol Propionate Ointment

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-70 years. 2. Definitely diagnosed as stable vitiligo; the concept of stable time VIDA. 3. No other skin diseases in the treated area. 4. No systemic treatment for vitiligo or no local treatment for the test site in the past 1 month. 5. Informed consent to the purpose and content of the study, and who can follow up as required, the minimum area of two or more places is greater than 2cm and the total body area is not more than 5%. 6. Perform blood routine and liver and kidney function for all patients before treatment, and do it once in the middle of treatment.

Exclusion criteria

Exclusion criteria: 1. Patients who use glucocorticoids and/or immunosuppressive agents. 2. Patients who have a history of photosensitivity or are sensitive to the drugs used. 3. Patients with liver and kidney dysfunction, diabetes, tuberculosis, cardiovascular and cerebrovascular diseases or other serious diseases. 4. The parts of face, neck and tender skin. 5. Pregnant women and breastfeeding period. 6. Take photosensitizer.

Design outcomes

Primary

Measure	Time frame
Dermatological quality of life;Signs and symptoms of skin lesions;	—

Countries

China

Contacts

Public ContactGao Xinghua

The First Affiliated Hospital of China Medical University

gaobarry@hotmail.com+86 13940152467

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026